VISN 5 MIRECC - General Publications 2009
About Us • Clinical • Education • Research
VISN 5 MIRECC home
Bennett, M. E. (2009). Assessment of substance use and substance use disorders in schizophrenia. Clinical Schizophrenia & Related Psychoses, 3(1), 50-63.
Bennett, M. E., Bellack, A. S., Brown, C. H., & DiClemente, C. (2009). Substance dependence and remission in schizophrenia: A comparison of schizophrenia and affective disorders. Addictive Behaviors, 34(10), 806-814.
Bennett, M. E., Nidecker, M., Kinnaman, J. S., Li, L., & Bellack, A. S. (2009). Examination of the Inventory of Drug Use Consequences with Individuals with Serious and Persistent Mental Illness and Co-occurring Substance Use Disorders. American Journal of Drug and Alcohol Abuse, 35(5), 385-390.
Borzekowski, D. L. G., Leith, J., Medoff, D. R., Potts, W., Dixon, L., Balis, T., Hackman, A. L., & Himelhoch, S. (2009). Use of the internet and other media for health information among clinic outpatients with serious mental illness. Psychiatric Services, 60, 1265-1268.
Chander, G., Himelhoch, S., Fleishman, J. A., Hellinger, J., Gaist, P., Moore, R. D., & Gebo, K. A. (2009). HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDs care, 21(5), 655-663.
Conley, R. R., Boggs, D. L., Kelly, D. L., McMahon, R. P., Dickinson, D., Feldman, S., Ball, M. P., & Buchanan, R. W. (2009). The effects of galantamine on psychopathology in chronic stable schizophrenia. Clinical Neuropharmacology, 32(2), 69-74.
Deutsch, S. I., Mastropaolo, J., Burket, J. A., & Rosse, R. B. (2009). An epigenetic intervention interacts with genetic strain differences to modulate the stress-induced reduction of fluazepam’s antiseizure efficacy in the mouse. European Nueropsychopharmacology, 19(6):398-401.
Dickinson, D., & Harvey P. D. (2009). Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophrenia Bulletin, 35(2), 403-414.
Dixon, L., Goldberg, R., Iannone V., Lucksted A., Brown, C., Kreyenbuhl, J., Fang, L., & Potts, W. (2009). Use of a critical time intervention to promote continuity of care after psychiatric inpatient hospitalization for severe mental illness. Psychiatric Services, 60(4), 451-458.
Dixon, L., Medoff, D., Goldberg, R., Lucksted, A., Kreyenbuhl, J., DeiClemete, C., Potts, W., Keith, J., Brown, C., Adams, C., & Afful, J. (2009). Is implmentation of the 5 A's of smoking cessation at community mental health centers effective for reduction of smoking by patients with serious mental illness? American Journal of Addictions, 18(5), 386-392.
Drapalski, A. L., Leith, J., & Dixon, L. (2009). Involving families in the care of persons with schizophrenia and other serious mental illnesses: History, evidence, and recommendations. Clinical Schizophrenia and Related Psychosis, 3(1), 39-49.
Gandhi, D., Welsh, C., Bennett, M., Carreño, J., & Himelhoch, S. (2009). Acceptability of Technology-based Methods Substance Abuse Counseling in Office Based Buprenorphine Maintenance for Opioid Dependence. American Journal on Addictions, 18(2), 182-183.
Goldberg, R., Tapscott, S., Calmes, C., & Wolfe, R. (2009). HIV and hepatitis knowledge among individuals with serious mental illness. Psychiatric Rehabilitation Journal, 33, 375-377.
Harvey, P. D., & Bellack, A. S. (2009). Toward a Terminology for Functional Recovery in Schizophrenia: Is Functional Remission a Viable Concept? Schizophrenia Bulletin, 35(2), 300-306.
Himelhoch, S., Leith, J., Goldberg, R., Kreyenbuhl, J., Medoff, D., & Dixon, L. (2009). Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who smoke. General Hospital Psychiatry, 31(1), 30-32.
Himelhoch, S., McCarthy, J., Gonaczy, D., Medoff, D., Kilbourne A., Goldberg, R., Dixon, L., & Blow, F. (2009). Understanding associations between serious mental illness and hepatitis C among veterans: a national multivariate analysis. Psychsomatics, 50(1), 30-37.
Hong, L. E., Turano, K. A., O’Neill, H. B., Hao, L., Wonodi, I., McMahon, R. P., & Thaker, G. K. (2009). Is motion perception deficit in schizophrenia a consequence of an eye-tracking abnormality. Biological Psychiatry, 65(12), 1079-1085.
Kelly, D. L., Buchanan, R. W., Boggs, D. L., McMahon, R. P., Dickinson, D., Nelson, M., Gold, J. M., Ball, M. P., Feldman, S., Lui, F., & Conley, R. R. (2009). A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. Journal of Clinical Psychiatry, 70(4), 518-525.
Kreyenbuhl, J., Nossell, I. R., & Dixon, L. B. (2009). Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literature. Schizophrenia Bulletin, 35(4), 696-703.
Lucksted, A., McNulty, K., Brayboy, L., & Forbes, C. (2009). Initial evaluation of the peer-to-peer program. Psychiatric Services, 60(2), 250-253.
Marx, C. E., Keefe, R. S., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., Savitz, A. J., Leimone, L. A., Dunn, L., Porcu, P., Morrow, A. L., & Shampine, L. J. (2009). Proof of concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology, 34(8), 1885-1903.
McCarthy, J. F., Dixon, L., & Slade E. (2009). In Reply: ACT and other case management services. Psychiatric Services, 60(4), 555-556.
McCarthy, J. F., Valenstein, M., Dixon, L., Visnic S., Blow, F. C., & Slade, E. P. (2009). Initiation of assertive community treatment among veterans with serious mental illness: clients and program factors. Psychiatric Services, 60(2), 196-201.
Mishra, S. I., Lucksted, A., Gioia, D., & Barnet, B. (2009). Needs and preferences for receiving mental health information in an African American focus group sample. Community Mental Health Journal, 45(2), 117-126.
Rowland, L. M., Spieker, E. A., Francis, A., Barker, P. B., Carpenter, W. T., & Buchanan, R. W. (2009). White matter alternation in deficit schizophrenia. Neuropsychopharmacology, 34(6), 1514-1522.
Schwartz, B. L., Parker, E. S., Rosse, R. B., & Deutsch, S. I. (2009). Recognition memory probes affect what is remembered in schizophrenia. Psychiatry Research, 167(1-2), 21-27.
Sherman, M. D., Fischer, E. P., Bowling, U. B., Dixon, L. B., Ridener, L., & Harrison, D. (2009). A new engagement strategy in a VA-based family psychoeducation program. Psychiatric Services, 60(2), 254-257.
Tenhula, W., Bennett, M. E., & Bellack, A. S. (2009). Behavioral Treatment of Substance Use in Schizophrenia. Journal of Clinical Psychology, 65(8), 831-841.
Wonodi, I., Hong, L. E., Stine, O. C., Mitchell, B. D., Elliott, A., Roberts, R. C., Conley, R. R., McMahon, R. P., & Thaker, G. K. (2009). Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 150B(2), 282-289.
NOTE: Names in bold are VISN 5 MIRECC Investigators
